- [Latest] Global CRISPR-based Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
- NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasomeâ„¢ Commercialization
- Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
- Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient
- Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
- MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
- MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
- Taurus Meds TRT Claims Evaluated: Powerful Testosterone Replacement Therapy & Taurus Charge ED Medication
- Assembly Biosciences Announces Upcoming Investor Conference Presentations
